# Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ENTA
## Company Profile
- Ticker: ENTA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Small Molecule Drugs, Immunology, Infectious Disease
## Stock Data
- Close: 13.22 USD
- Market cap: 349812911.4 USD
- Last updated: 2026-08-05
## Business Overview
### Small-Molecule Research Platform
Enanta Pharmaceuticals discovers and develops oral small molecules for virology and immunology. Its portfolio applies structure-based drug design to targets that may support convenient, once-daily treatment.
### EDP-978 KIT Inhibitor
EDP-978 is an oral KIT inhibitor in Phase 1 development for chronic urticaria and potentially other mast-cell-mediated diseases.
### EPS-3903 STAT6 Inhibitor
EPS-3903 is an oral STAT6 inhibitor intended for atopic dermatitis and other type 2 inflammatory diseases currently treated with injectable biologics.
### MRGPRX2 Discovery Program
Enanta is also developing inhibitors of MRGPRX2, a mast-cell and peripheral-neuron receptor implicated in urticaria, asthma, prurigo nodularis and migraine.
### Respiratory Antiviral Program
Zelicapavir is an oral antiviral being prepared for pivotal development in high-risk adults with respiratory syncytial virus. EDP-323 provides a second RSV mechanism that may be used alone or in combination.
## Why The Stock Is Moving

As of Aug 5, 2026, ENTA closed down 0.75% at $13.22. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline Phase 1 data for EDP-978 in the fourth quarter of 2026.
- IND submission for EPS-3903 in the second half of 2026.

## Drug Assets

- EDP-978

## Recent News
- 2026-06-23 09:10 EST — [Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-partner-abbvie-receives-european-commission-approval-of-m-5130ab2a) — Source: Enanta Pharmaceuticals
- 2026-06-18 11:00 EST — [Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-announces-advancement-of-its-zelicapavir-clinical-develop-bcf5354e) — Source: Enanta Pharmaceuticals
- 2026-05-28 11:00 EST — [Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference) — Source: Enanta Pharmaceuticals
- 2026-05-11 20:01 EST — [Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-march-31-2026) — Source: Enanta Pharmaceuticals
- 2026-05-04 11:00 EST — [Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-data-for-its-respiratory-syncytial-virus-and-stat6-inhibitor-programs-at-the-american-thoracic-society-international-conference-2026) — Source: Enanta Pharmaceuticals